North America Advanced Infusion Systems Market

North America Advanced Infusion Systems Market Size ( 2024 to 2029)

North America Advanced Infusion Systems Market was worth USD 3.45 million in 2024 and estimated to reach USD 4.54 million by the end of 2029 with a CAGR of 5.62 %. 

The factor which is significantly boosting the growth of the advanced infusion system market in North America is the rise in the prevalence of chronic diseases, diabetes, and cancer.

The expansion of healthcare in North America owing to technological advancements is helping the manufactures and key players to enlarge their distribution networks and productivity in manufacturing capabilities which are fueling up the growth of North America's advanced infusion system market. Other benefits associated with advanced infusion systems such as mobility of system, practical application of therapeutics, enhanced safety of patients, visual monitoring, and low risk for the users are also catalyzing the growth of North America's advanced infusion system business. 

The emergence of novel and technologically advanced infusion systems and the increasing popularity of ergonomically well-designed infusion systems are the factors that are assumed to create lucrative growth opportunities for key market players in the advanced infusion systems market during the forecast period in North America. Increasing investments from the private and public sectors in this region for the research and development of effective drug delivery systems is likely to offer a number of growth opportunities for the stakeholders in the area. Continuously increasing prevalence of geriatric and chronic disorders population are providing growth opportunities for the key players functioning in the North America advanced infusion market during the outlook period.

Stringent rules and regulations for the approval of the advanced infusion systems in North America are posing a major problem for the key players, which are limiting the growth of North America's advanced infusion systems market. The lack of trained professionals available for handling advanced devices is challenging the growth of the North American market. Inaccurate medication through infusion pumps may lead to side effects which are limiting the growth of the advanced infusion systems market in this area.

This research report on the North America Advanced Infusion Systems Market is segmented & sub-segmented into the following categories.

North America Advanced Infusion Systems Market By Application Type

• Clinical Nutrition
• Chemotherapy
• Pain Management
• Diabetes
• Asthma Treatment

North America Advanced Infusion Systems Market By Product Type

• Disposable Infusion System
• Elastomeric Infusion System
• Ambulatory Infusion System
• Volumetric Infusion System
• Patient Controlled Analgesia Pump
• Syringe Infusion System
• Implantable Infusion System

North America Advanced Infusion Systems Market By End-Users

• Diagnostic Centers
• Hospitals
• Ambulatory Surgical Centers

North America Advanced Infusion Systems Market By Country

• United States
• Canada
• Rest of North America

The U.S. Advanced Infusion Systems Market is dominating the growth of the North American Advanced Infusion Systems Market, which is likely to grow further during the projection period owing to factors such as the increased prevalence of chronic diseases and the rise in the adoption rate of ambulatory pumps. The Canada market is contributing a significant share of revenues and is foreseen to maintain the trend over the forecast period due to an increased percentage of the geriatric population affected with chronic disorders and diabetes, and the availability of advanced health care facilities in the region.

Key Market Players

Companies playing a promising role in the North American Advanced Infusion Systems Market profiled in this report are Hospira, AngioDynamics, Inc., Medtronic, Inc., Terumo Corporation, Johnson & Johnson, CareFusion Corporation, Animas Corporation, Baxter International, Inc., B. Braun Melsungen AG, I-Flow Corporation and F. Hoffmann-La Roche Ltd.